Celltrion, Inc. (KRX:068270)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 33.91T |
| Revenue (ttm) | 3.56T |
| Net Income (ttm) | 422.69B |
| Shares Out | 213.78M |
| EPS (ttm) | 1,947.62 |
| PE Ratio | 81.43 |
| Forward PE | 32.14 |
| Dividend | 714.29 (0.45%) |
| Ex-Dividend Date | Dec 27, 2024 |
| Volume | 269,475 |
| Average Volume | 487,160 |
| Open | 160,600 |
| Previous Close | 159,900 |
| Day's Range | 158,100 - 160,750 |
| 52-Week Range | 152,667 - 200,952 |
| Beta | 0.50 |
| RSI | 39.31 |
| Earnings Date | May 9, 2025 |
About Celltrion
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase... [Read more]
Financial Performance
In 2024, Celltrion's revenue was 3.56 trillion, an increase of 63.45% compared to the previous year's 2.18 trillion. Earnings were 422.69 billion, a decrease of -21.09%.
Financial StatementsNews
Shilpa Medicare settles Celltrion arbitration case with $3.4 million agreement
Shilpa Medicare Limited has entered into a settlement agreement with Celltrion Inc., a South Korea-based pharmaceutical company, thereby resolving an ongoing arbitration dispute. The company informed ...
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
Remdantry™ (previously known as Inflectra®), developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar infliximab in Canada and will be commercially available across Canada ...
Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian mark...
FDA approves Celltrion's biosimilar of J&J's Stelara
Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada
Omlyclo™ (CT-P39) is the first and only omalizumab biosimilar referencing Xolair® approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria (CIU), allergic asthma, ...